Status:
UNKNOWN
HEParin Antagonisation in Transcatheter Aortic Valve Implantation
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Conditions:
Aortic Valve Stenosis
Transcatheter Aortic Valve Implantation
Eligibility:
All Genders
18+ years
Brief Summary
Unfractioned heparin is usually given in a defined dosage during transfemoral TAVI. Activated Clotting Time (ACT) is usually used to measure the heparin effect. ACT-analysis is easy to perform at the ...
Eligibility Criteria
Inclusion
- Severe aortic valve Stenosis
- transfemoral TAVI as best therapy option
- unfractioned heparin for periprocedural anticoagulation
Exclusion
- known hypersensitivity /allergy to unfractioned heparin or protamine
- acute systemic infection
- pre procedural started and ongoing intravenous therapy with unfractioned heparin
- severe periprocedural adverse event with the need for emergency surgery (with or with our CPB)
- refusal of the patient to participate
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05422170
Start Date
July 1 2022
End Date
April 1 2023
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München
Munich, Bavaria, Germany, D80636